###begin article-title 0
Gender Differences in Genetic Risk Profiles for Cardiovascular Disease
###end article-title 0
###begin p 1
Conceived and designed the experiments: KS MA KKristiansson KA JK SK KKuulasmaa AE MP VS LP. Performed the experiments: KS MA KKristiansson KA PE JS. Analyzed the data: KS MA KKristiansson OS SR JK SK KKuulasmaa MP LP. Contributed reagents/materials/analysis tools: MN EV PJ VS. Wrote the paper: KS MA KKristiansson OS SR KA JK SK MN PE EV PJ JS KKuulasmaa AE MP VS LP. Responsible for the DNA sample management: MA. Participated in SNP selection: MA KKristiansson KA MP. Participated in genotyping: MA KKristiansson KA PE JS. Participated in data analyses: KS MA KKristiansson SR MP. Responsible for the statistical analysis of the data: OS. Participated in data management, case-cohort selection, and statistical analysis: JK SK. Responsible for phenotype data quality assessment: MN. Participated in recruitment of the FINRISK cohorts: EV PJ VS. Participated in whole genome amplification of DNA samples: JS. Responsible for data management and case-cohort selection: KKuulasmaa. Participated in study design: KS KKuulasmaa AE MP VS. MORGAM Project Coordinator: AE. Participated in the assessment of the clinical diagnoses: VS. Has had an overall responsibility of the study design and data analyses: LP. Responsible for SNP selection: KS. Responsible for DNA sample quality, whole genome amplification of DNA, genotyping, and writing the manuscript: KS. Holds overall responsibility of the data presented: KS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 89 94 <span type="species:ncbi:9606">women</span>
###xml 99 102 <span type="species:ncbi:9606">men</span>
Cardiovascular disease (CVD) incidence, complications and burden differ markedly between women and men. Although there is variation in the distribution of lifestyle factors between the genders, they do not fully explain the differences in CVD incidence and suggest the existence of gender-specific genetic risk factors. We aimed to estimate whether the genetic risk profiles of coronary heart disease (CHD), ischemic stroke and the composite end-point of CVD differ between the genders.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 388 397 388 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1801020</italic>
###xml 509 519 509 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs11673407</italic>
###xml 759 768 759 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs3742264</italic>
###xml 838 847 838 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 988 997 988 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2069840</italic>
###xml 224 227 <span type="species:ncbi:9606">men</span>
###xml 232 237 <span type="species:ncbi:9606">women</span>
###xml 355 358 <span type="species:ncbi:9606">men</span>
###xml 363 368 <span type="species:ncbi:9606">women</span>
###xml 960 965 <span type="species:ncbi:9606">women</span>
###xml 977 980 <span type="species:ncbi:9606">men</span>
###xml 1082 1085 <span type="species:ncbi:9606">men</span>
###xml 1097 1102 <span type="species:ncbi:9606">women</span>
###xml 1212 1217 <span type="species:ncbi:9606">women</span>
###xml 1327 1332 <span type="species:ncbi:9606">women</span>
###xml 1342 1345 <span type="species:ncbi:9606">men</span>
We studied in two Finnish population cohorts, using the case-cohort design the association between common variation in 46 candidate genes and CHD, ischemic stroke, CVD, and CVD-related quantitative risk factors. We analyzed men and women jointly and also conducted genotype-gender interaction analysis. Several allelic variants conferred disease risk for men and women jointly, including rs1801020 in coagulation factor XII (HR = 1.31 (1.08-1.60) for CVD, uncorrected p = 0.006 multiplicative model). Variant rs11673407 in the fucosyltransferase 3 gene was strongly associated with waist/hip ratio (uncorrected p = 0.00005) in joint analysis. In interaction analysis we found statistical evidence of variant-gender interaction conferring risk of CHD and CVD: rs3742264 in the carboxypeptidase B2 gene, p(interaction) = 0.009 for CHD, and rs2774279 in the upstream stimulatory factor 1 gene, p(interaction) = 0.007 for CHD and CVD, showed strong association in women but not in men, while rs2069840 in interleukin 6 gene, p(interaction) = 0.004 for CVD, showed strong association in men but not in women (uncorrected p-values). Also, two variants in the selenoprotein S gene conferred risk for ischemic stroke in women, p(interaction) = 0.003 and 0.007. Importantly, we identified a larger number of gender-specific effects for women than for men.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 363 368 <span type="species:ncbi:9606">women</span>
###xml 380 383 <span type="species:ncbi:9606">men</span>
A false discovery rate analysis suggests that we may expect half of the reported findings for combined gender analysis to be true positives, while at least third of the reported genotype-gender interaction results are true positives. The asymmetry in positive findings between the genders could imply that genetic risk loci for CVD are more readily detectable in women, while for men they are more confounded by environmental/lifestyle risk factors. The possible differences in genetic risk profiles between the genders should be addressed in more detail in genetic studies of CVD, and more focus on female CVD risk is also warranted in genome-wide association studies.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-World1">[1]</xref>
###xml 550 553 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-BarrettConnor1">[2]</xref>
###xml 554 557 554 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Yusuf1">[7]</xref>
###xml 679 682 679 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-BarrettConnor1">[2]</xref>
###xml 749 752 749 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Bak1">[8]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Lusis1">[10]</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Touze1">[11]</xref>
###xml 961 965 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Lusis1">[10]</xref>
###xml 1005 1009 1005 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy1">[12]</xref>
###xml 1236 1240 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Pilia1">[13]</xref>
###xml 1375 1379 1375 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy1">[12]</xref>
###xml 347 350 <span type="species:ncbi:9606">men</span>
###xml 355 360 <span type="species:ncbi:9606">women</span>
###xml 362 367 <span type="species:ncbi:9606">Women</span>
###xml 431 434 <span type="species:ncbi:9606">men</span>
###xml 536 539 <span type="species:ncbi:9606">men</span>
###xml 544 549 <span type="species:ncbi:9606">women</span>
###xml 871 876 <span type="species:ncbi:9606">women</span>
###xml 882 885 <span type="species:ncbi:9606">men</span>
###xml 1230 1235 <span type="species:ncbi:9606">women</span>
According to world statistics for 2006, cardiovascular diseases (CVD) are responsible for 30% of all deaths globally, and are the leading cause of death amongst non-communicable diseases. Cardiovascular diseases are also responsible for 10% of the global burden of disease [1]. Differences in CVD incidence, complications and burden exist between men and women. Women are afflicted with cardiovascular disease at an older age than men, and many risk variables for coronary heart disease (CHD) and stroke have different distributions in men and women [2]-[7]. However, the differences in lifestyle factors do not fully explain the differences in CVD incidence between the genders [2]. Genetic factors also contribute to CHD and stroke susceptibility [8]-[10]. A recent large population-based prospective study suggested that heritability of ischemic stroke was greater in women than men [11]. Some of the traditional CVD risk factors also have high heritability [10], some of which show gender differences [12]. A large scale study of CVD traits in a Sardinian population showed that for several traits in which heritability estimates differed by gender, for example weight and hip circumference, the heritability was larger among women [13]. The evidence for gender differences in trait heritabilities implies possible gender-gene interaction in the etiology of these traits [12].
###end p 9
###begin p 10
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Lusis1">[10]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy1">[12]</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Helgadottir1">[14]</xref>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Wellcome1">[19]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy2">[20]</xref>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Yamada2">[25]</xref>
###xml 706 710 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Yamada3">[26]</xref>
###xml 952 956 952 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy3">[27]</xref>
###xml 1007 1011 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Helgadottir1">[14]</xref>
###xml 1012 1016 1012 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Samani1">[17]</xref>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Wellcome1">[19]</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Matarin1">[28]</xref>
###xml 583 586 <span type="species:ncbi:9606">men</span>
###xml 591 596 <span type="species:ncbi:9606">women</span>
###xml 664 667 <span type="species:ncbi:9606">men</span>
###xml 672 677 <span type="species:ncbi:9606">women</span>
###xml 834 842 <span type="species:ncbi:9606">patients</span>
The effect of genetic variables on CHD and ischemic stroke has been studied for several decades, yet there are only a few consistent risk factors identified to date [10], [12], [14]-[19]. These genetic studies include few large scale candidate gene studies, as well as numerous smaller studies, and very recently several genome-wide association studies. Most of the large scale candidate gene studies published so far on CHD or stroke have performed combined analyses of both genders, using gender as a covariate [20]-[25]. In a Japanese case-control study of myocardial infarction, men and women were analyzed separately, and the significant results obtained for men and women were for different variants [26], indicating different genetic risk factors. In a large-scale genetic association study of the metabolic syndrome among CHD patients, McCarthy and colleagues identified several variants which displayed significant genotype-gender interaction [27]. In recent genome-wide association studies of CHD [14]-[17], [19] and ischemic stroke [28], the association results were reported for the combined study sample of both genders.
###end p 10
###begin p 11
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Evans2">[29]</xref>
###xml 1072 1076 1072 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 1099 1111 1099 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1, SELS,</italic>
###xml 1115 1122 1115 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SELENOS</italic>
###xml 1163 1167 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 1169 1173 1169 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 1157 1162 <span type="species:ncbi:9606">women</span>
We estimated the effect of genetic variation on CHD, ischemic stroke and the composite end-point of CVD in two prospectively followed population cohorts. Our study had a case-cohort design on the FINRISK-92 and -97 cohorts participating in the MORGAM Project [29]. We selected 46 genes for study as putatively involved in cardiovascular pathobiology, based on their function, previous association with cardiovascular disease, and/or relevant phenotype in animal models. These genes represent a selected array of pathways, including lipid and energy metabolism, inflammation, coagulation, and thrombosis. We assessed the risk associated with common variation in each gene and CHD, ischemic stroke, and CVD while the cohort setting allowed us to control for classic CVD risk factors. We also assessed whether the variants affect relevant quantitative traits that are related to CVD risk: lipid and C-reactive protein (CRP) levels, blood pressure, body mass index (BMI), and waist/hip ratio (WHR). Our previous analysis of candidate genes like upstream stimulatory factor 1 (USF1) and Selenoprotein S (SEPS1, SELS, or SELENOS) mainly showed genetic effects in women [30], [31]. In this study, we therefore proceeded with a formal genotype-gender interaction analysis for all variants, and show that for several of the associated variants, there is evidence for statistical interaction between gender and genotype.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
FINRISK cohort description
###end title 13
###begin p 14
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Vartiainen1">[32]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Evans2">[29]</xref>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro1">[33]</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Kulathinal2">[35]</xref>
FINRISK surveys are carried out every 5 years to assess the prevalence and risk factors of CVD in Finland [32]. Baseline information on all randomly sampled individuals includes anthropometric measurements, serum lipids, blood pressure and questionnaire data on CVD risk factors. Information on fatal and non-fatal coronary and stroke events and all-cause mortality during the follow-up period is obtained from national registers. We utilized the FINRISK-92 cohort (n = 5999) and FINRISK-97 cohort (n = 8141), which have been followed up for 10 and 7 years, respectively. On these large cohorts, we conducted a case-cohort study, as previously described in detail [29], [31], [33]-[35]. The cohorts constituted respondents to surveys of independent random samples of the same geographically defined population. The resulting few overlaps were identified on the basis of personal ID codes, unique to every resident of Finland, and removed from the FINRISK-97 case-cohort set to ensure there was no overlap between the sets used for the analyses.
###end p 14
###begin p 15
###xml 1177 1181 1177 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Evans2">[29]</xref>
###xml 1183 1187 1183 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 1189 1193 1189 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro1">[33]</xref>
###xml 1194 1198 1194 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Kulathinal2">[35]</xref>
###xml 1261 1269 1261 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t001">Tables 1</xref>
###xml 1274 1275 1274 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t002">2</xref>
###xml 1281 1293 <span type="species:ncbi:9606">participants</span>
###xml 1500 1512 <span type="species:ncbi:9606">participants</span>
We initially studied the FINRISK-92 case-cohort set, which consisted of a total of 190 incident CHD cases, 66 incident ischemic stroke cases, 219 individuals with a history of either CHD or stroke event, 276 individuals who died during the follow-up, and a random sample (sub-cohort) of 398 individuals from the cohort. We also analyzed a second case-cohort set selected from the FINRISK-97 cohort, for genes associated with risk for CHD, ischemic stroke, the composite end-point of CVD or all-cause mortality, or strongly associated with quantitative traits in the FINRISK-92 case-cohort set. This sample included 210 incident CHD cases, 84 incident stroke cases, 436 individuals with a history of either CHD or stroke event, 352 individuals who died during the follow-up, and 407 sub-cohort individuals. The sub-cohort was a sex- and geographic-region stratified random sample, drawn from each of the original cohorts with unequal sampling probabilities so that the age distribution was similar to the cases. The selection procedure for the cases and the sub-cohort, and the exact diagnostic criteria used for CHD and ischemic stroke have been described in detail previously [29], [31], [33]-[35]. The case-cohort sets included in this study are described in Tables 1 and 2. All participants gave informed consent. In 1992 it was not yet customary to ask for a written consent, thus only oral informed consent exists for that survey. In 1997 a written informed consent was obtained from all survey participants. The law about the National Public Health Institute of Finland gives the Institute a possibility to also use the samples from the 1992 survey for public health research. The study was approved by the Ethics Committee of the National Public Health Institute of Finland and conformed to the principles expressed in the Declaration of Helsinki.
###end p 15
###begin title 16
Number of individuals in each of the case status categories in the FINRISK-92 and FINRISK-97 case-cohort study.
###end title 16
###begin p 17
Random sample of the cohort, which included also some cases.
###end p 17
###begin p 18
These were incident during follow-up.
###end p 18
###begin p 19
Cardiovascular disease at baseline.
###end p 19
###begin title 20
Baseline characteristics according to case status, mean (std).
###end title 20
###begin p 21
Sub-cohort individuals free of CVD at the end of follow up.
###end p 21
###begin p 22
Mean of two measurements.
###end p 22
###begin title 23
Quality control of DNA samples
###end title 23
###begin p 24
###xml 234 241 234 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t001">Table 1</xref>
###xml 858 862 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Silander1">[36]</xref>
We implemented several quality control measures to minimize errors associated with DNA sample handling and DNA quality, and excluded a total of 19 samples chosen as cases or in the sub-cohort. These 19 individuals are not included in Table 1. A gender-specific PCR test identified a total of 9 samples (0.4%) that had a different gender than expected, and they were subsequently excluded from the study. We also verified that the DNA sample was of good quality by testing five highly polymorphic microsatellite markers for each sample. In these analyses, one sample was found to be contaminated and was excluded. DNA samples with low DNA yield (<7.5 microg of genomic DNA) as measured by fluorescent label PicoGreen (Invitrogen, Carlsbad, CA, USA) were subjected to whole genome amplification before genotyping, followed by additional quality control checks [36]. A total of five samples were excluded due to biased whole genome amplification, and a further 4 samples were excluded due to extremely low quantities of DNA which was insufficient for whole genome amplification.
###end p 24
###begin title 25
Variant selection
###end title 25
###begin p 26
###xml 575 576 575 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Carlson1">[37]</xref>
###xml 1150 1156 1150 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(APOE)</italic>
###xml 1167 1171 1167 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT)</italic>
###xml 1186 1192 1186 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPIN1)</italic>
###xml 1295 1299 1295 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Enattah1">[38]</xref>
###xml 1300 1304 1300 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Suviolahti1">[41]</xref>
###xml 1407 1415 1407 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s001">Table S1</xref>
For each gene, we aimed to genotype a set of variants that would capture the common variation present in the gene, as well as variants that have been previously associated with CVD or related traits. For the majority of the genes, haplotype-tagging single nucleotide polymorphism (SNP) variants were selected from the SeattleSNPs database (). The SeattleSNPs project has resequenced the genes using 24 Centre d'Etude du Polymorphisme Humain DNA samples, and tag SNPs have been selected using LDSelect, an algorithm that is based on the linkage disequilibrium (LD) statistic r2[37]. We selected tag SNPs from each multi-SNP bin with a frequency >10%. For genes that were not included in the SeattleSNPs sequencing project, we selected variants from public databases (Celera, dbSNP), at approximately 5 kb distance from one another, giving priority to variants with known frequency information. Once HapMap phase I data were available, we selected additional variants to better capture the common variation in these genes. More detailed information about gene cladistics, sequence and haplotype structure information was available for apolipoprotein E (APOE), lactase (LCT), and lipin 1 (LPIN1)-genes, and here variant selection was based on previously published sequencing and haplotype analysis [38]-[41]. A full list of the variants selected for study and successfully genotyped (see below) is provided in Table S1.
###end p 26
###begin title 27
Variant genotyping
###end title 27
###begin p 28
###xml 64 72 64 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s001">Table S1</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Silander1">[36]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-TikkaKleemola1">[42]</xref>
###xml 789 793 789 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 838 846 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs429358</italic>
###xml 851 857 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs7412</italic>
###xml 940 944 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Janis1">[43]</xref>
###xml 1259 1263 1259 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 1265 1269 1265 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro2">[44]</xref>
###xml 1455 1459 1455 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Silander1">[36]</xref>
Variant genotyping was done using several genotyping platforms (Table S1). Approximately 5.5% of the genotypes were created with an in-house developed method of allele-specific primer extension on microarrays, as previously described [36]. Approximately 93.0% of the genotypes were produced with the MassARRAY System (Sequenom, San Diego, CA, USA), either with the homogeneous Mass Extension (hME) reaction or iPLEX reaction, using the protocols recommended by the manufacturer with these modifications: hME reactions were carried out with 5-7.5 ng of DNA and for the majority of the variants, the hME extension reaction was run using TERMIPol DNA polymerase (Solis Biodyne OU, Tartu, Estonia) [42] instead of ThermoSequenase (GE Healthcare Life Sciences, Chalfont St. Giles, UK). The two APOE variants that define the epsilon genotypes (rs429358 and rs7412) were genotyped on the MassARRAY with a modified protocol as previously described [43] (full protocol available from authors upon request). Three of the variants were genotyped with other platforms: rs4340 was genotyped by a PCR assay followed by separation on 2% agarose gel with ethidium bromide staining and rs28665122 and rs3216183 were genotyped with TaqMan (Applied Biosystems, Foster City, CA) [30], [44]. For 100 samples where inadequate amount of genomic DNA was available, the DNA was amplified with GenomiPhi DNA amplification kit (GE Healthcare Life Sciences), as previously described [36].
###end p 28
###begin p 29
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Silander1">[36]</xref>
###xml 645 649 645 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-TikkaKleemola1">[42]</xref>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Silander2">[45]</xref>
###xml 1116 1125 1116 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1926446</italic>
###xml 1127 1136 1127 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs3212478</italic>
###xml 1142 1151 1142 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1081106</italic>
Before genotyping the FINRISK case-cohort samples we genotyped all variants on 60 anonymous Finnish trio samples and 180 unrelated control samples. The FINRISK samples were genotyped in plates containing 2% negative control samples, 2% known duplicate samples, and 5% blind duplicate samples to allow assessment of genotyping quality. The disease status of each individual genotyped was unknown to the genotyping laboratory and samples from cases and sub-cohort individuals were distributed on the plates independently of the disease status. All genotypes were manually reviewed for various quality control aspects as previously described [36], [42], [45]. The genotyping success rate for each variant included in the analysis was >90%, with an average genotyping success of 95.3%. Among the 27,522 successful blind duplicate genotypic pairs, we detected 37 genotypic inconsistencies (99.87% concordance between genotypes). All variants included in analyses were in Hardy-Weinberg equilibrium (HWE) in the sub-cohort sample (p>0.01). A single Mendelian error was identified for 3 variants among the 60 trio samples (rs1926446, rs3212478, and rs1081106). However, since the genotypes for these variants were in HWE and no errors were detected among known and blind duplicates, these variants were included in the analysis.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-OConnell1">[46]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Barrett1">[47]</xref>
Genotype frequencies in sub-cohort individuals were tested for deviation from HWE using Pearson's chi-square test statistics with 1 degree of freedom for bi-allelic variants and 3 for three-allelic variants, applying a threshold of p<0.01. For variants in which one of the genotype groups had less than 5 individuals, HWE was calculated using an exact test. Allele segregation within trio families was analyzed with the PedCheck program [46]. Pair-wise LD between the variants in each gene, haplotype frequencies, and haplotype tags were assessed with Haploview software version 3.32 [47]. For variants in high LD with each other (r2>0.95), only one of the results is shown.
###end p 31
###begin p 32
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Prentice1">[48]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Kulathinal1">[34]</xref>
###xml 1073 1078 <span type="species:ncbi:9606">women</span>
###xml 1083 1086 <span type="species:ncbi:9606">men</span>
###xml 1186 1189 <span type="species:ncbi:9606">men</span>
###xml 1194 1199 <span type="species:ncbi:9606">women</span>
###xml 1524 1527 <span type="species:ncbi:9606">men</span>
###xml 1532 1537 <span type="species:ncbi:9606">women</span>
###xml 1626 1629 <span type="species:ncbi:9606">men</span>
###xml 1633 1638 <span type="species:ncbi:9606">women</span>
###xml 2328 2331 <span type="species:ncbi:9606">men</span>
###xml 2336 2341 <span type="species:ncbi:9606">women</span>
Time-to-event analysis was used to assess whether any of the tested allelic variants have effect on the incidence of CHD, ischemic stroke, or CVD. The effects under recessive, dominant and multiplicative models of individual variants were tested using the proportional hazards regression model where the case-cohort design was taken into account by applying a modification of the Prentice weighting [48], with the non-case sub-cohort members and sub-cohort cases before events weighted with the inverses of their individual inclusion probabilities to account for the over-sampling of cases[34]. Estimation of model parameters and standard errors was carried out in R statistical environment, using the coxph function of the package survival and its robust variance estimator. We adjusted for classic CVD risk factors: smoking, high density lipoprotein-cholesterol (HDL-C), non-HDL-cholesterol, history of diabetes, BMI, and hypertension, as well as geographic region (western Finland, northern Finland, and eastern Finland), and cohort (and gender for combined analysis in women and men). Age was used in the models as the time scale. We fitted two types of models. In the first model, men and women from both cohorts were analyzed jointly, as described above. In the second model, we carried out a test for genotype-gender interaction, defined as a departure from multiplicative, dominant or recessive model, using similar regression models and testing the null hypothesis of equality of genotype effect parameters between men and women. We report results in which the variant genotype specific p-value is </=0.01 for either men or women. We verified that these results do not stem from a single cohort by testing the null hypothesis of equality of genotype effect parameters between FINRISK-92 and FINRISK-97 cohorts, using a similar regression model. For variants that conferred a risk at p<0.05 for CHD, we also studied the association in prevalent CHD cases (documented or self-reported myocardial infarction or unstable angina pectoris at baseline), using healthy sub-cohort subjects as controls. The analysis of prevalent cases was carried out using logistic regression, again with inverse sampling probability weighting, and using age, cohort and geographic region, and gender as covariates for the combined analysis of men and women. Analysis of haplotype effects was done for two variants of the F12 gene that were not in very high LD with each other and were both associated at p<0.01 with CHD and CVD. Haplotype analysis was done with an additive model, in which the common haplotype (containing the 'non-risk' alleles) was used as reference, and modeling an additive effect for the other haplotypes, in a weighted Cox proportional hazards model, applying the same weighting scheme and covariates that were used for single variant analysis, and using the PHREG procedure implemented in SAS version 9.1.3 SP4. Haplotype uncertainty was taken into account using multiple imputations, where a sample of haplotypes was obtained using Phase 2.1.1 software and the analysis was repeated for each sampled haplotype pair.
###end p 32
###begin p 33
###xml 1115 1118 <span type="species:ncbi:9606">men</span>
###xml 1123 1128 <span type="species:ncbi:9606">women</span>
Additionally, we tested whether allelic variants were associated with quantitative traits measured at baseline in sub-cohort individuals without a history of CVD. The lipid variables studied were: serum total cholesterol, HDL-C, triglycerides, and low density lipoprotein-cholesterol (LDL-C). LDL-C was calculated from measured values of total cholesterol, HDL-C and triglycerides using Friedewald's formula and excluding individuals with triglyceride value >4.0 mmol/l. Additional variables studied were mean blood pressure (average of systolic and diastolic blood pressure, each value based on two subsequent measurements), high sensitivity CRP, BMI, and WHR. Association of the variants with baseline measurements was tested using standard linear regression, employing additive, dominant, and recessive models, while adjusting for cohort, age, geographic region, and gender. Tests for genotype-gender interaction, defined as a departure from additive, dominant or recessive model, were carried out using similar regression models and testing the null hypothesis of equality of genotype effect parameters between men and women. Individuals using lipid lowering medication were excluded from the analyses of lipid variables, and individuals using drugs for hypertension were excluded from the analysis of blood pressure. We used logarithmic transformation for CRP and triglycerides. We verified that the results reported do not stem from a single cohort by testing the null hypothesis of equality of genotype effect parameters between FINRISK-92 and FINRISK-97 cohorts, using a similar regression model.
###end p 33
###begin p 34
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-SinnwellJP1">[49]</xref>
For genes in which two or more variants (not in perfect LD) were associated at p<0.01 with a given quantitative trait, we also performed haplotype analysis to discern which allelic haplotype might be contributing to variation in the trait. Haplotype tagging variants were identified with the Haploview software version 3.32 using default settings. Analyses with the haplotype-tagging variants were performed with the haplo.stats package of the R statistical software [49], using the function haplo.glm with an additive model, and adjusting for age, cohort, geographic region and gender. The haplo.glm function estimates haplotype frequencies with the EM algorithm and calculates for each haplotype linear regression coefficient and p-value, comparing each haplotype to a base haplotype, defined as the most common haplotype. Rare haplotypes (frequency <0.05) were combined with the base haplotype for this analysis. The global p-value for haplotype effect coefficients was calculated for the null hypothesis of no effect for any haplotype.
###end p 34
###begin p 35
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro1">[33]</xref>
###xml 179 184 <span type="species:ncbi:9606">women</span>
###xml 189 192 <span type="species:ncbi:9606">men</span>
For the initial analyses of the FINRISK-92 case-cohort alone, time-to-event analyses and quantitative trait analyses were done as previously described [30], [31], [33], analyzing women and men both separately and together. We did not perform formal gender-genotype interaction analysis or haplotype analysis at this stage.
###end p 35
###begin p 36
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Wellcome1">[19]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Efron1">[50]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Efron2">[51]</xref>
###xml 737 741 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Strimmer1">[52]</xref>
###xml 819 823 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Kulathinal1">[34]</xref>
###xml 1075 1078 <span type="species:ncbi:9606">men</span>
###xml 1108 1113 <span type="species:ncbi:9606">women</span>
In reporting the findings, we used a cut-off value of 0.01 for the p-values and reported uncorrected p-values. The cut-off value of 0.01 corresponds to posterior odds 6:1 of a finding being a true signal when we expect to see two signals among the 27 independent genes and our power is 70% (see The Wellcome Trust Case-control Consortium's 2007 paper for details) [19]. The effect of multiple testing was addressed with standard Q-Q-plots for the individual test statistics and with false discovery rate (FDR) analysis [50], [51]. The tail-area FDR statistic for a group of tests can be interpreted as the expected proportion of null results given the observed test statistics. The analysis was carried out using the R package "fdrtool" [52]. The method used for power simulations is described in more detail elsewhere [34]. The reported results are for both cohorts combined, for tests of the null hypothesis of no genotype effects (or no genotype-gender interaction) at 1% significance level. While simulating genotype-gender interaction we assumed no genotype effects for men while varying the effect for women.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
Study outline
###end title 38
###begin p 39
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 178 186 178 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t001">Tables 1</xref>
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t002">2</xref>
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t003">Table 3</xref>
###xml 359 367 359 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s001">Table S1</xref>
###xml 454 457 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Russo1">[53]</xref>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Sahi1">[54]</xref>
###xml 712 719 712 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 985 989 985 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBD</italic>
###xml 1014 1019 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1</italic>
###xml 1043 1045 1043 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5</italic>
###xml 1059 1063 1059 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROC</italic>
###xml 1105 1110 1105 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ICAM1</italic>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 1124 1128 1124 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro1">[33]</xref>
###xml 1130 1134 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Auro2">[44]</xref>
###xml 68 74 <span type="species:ncbi:9606">person</span>
###xml 123 129 <span type="species:ncbi:9606">person</span>
###xml 1260 1263 <span type="species:ncbi:9606">men</span>
###xml 1268 1273 <span type="species:ncbi:9606">women</span>
The case-cohort sets from the FINRISK-92 (10 year follow up, 57,858 person-years) and FINRISK-97 (7 year follow up, 54,577 person-years) population cohorts [31] are presented in Tables 1 and 2. The list of genes and the number of variants successfully genotyped for each gene are presented in Table 3, and detailed information on all variants is presented in Table S1. In addition to known CVD candidate genes, we explored the effect of variation in the LCT gene on CVD risk and CVD related quantitative traits, because of previous findings of reduced triglyceride and cholesterol values in individuals with lactose malabsorption [53], [54]. We also studied one novel gene, apolipoprotein B mRNA editing enzyme (APOBEC2), which is located directly under a linkage peak (lod score of 4.44) for total cholesterol in our linkage study of 5775 individuals from twin families from the GenomEUtwin (). Individual results of the analysis for several of the genes have already been published: USF1, thrombomodulin (THBD), SEPS1, coagulation factor V (F5), protein C (PROC), and intercellular adhesion molecule 1 (ICAM1) [30], [31], [33], [44]. We include these genes here to provide a more complete picture of the observed difference in genetic susceptibility between men and women, and because formal genotype-gender interaction analysis was not reported for any of the genes in our previous publications.
###end p 39
###begin title 40
The genes included in the current study.
###end title 40
###begin p 41
###xml 34 42 34 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003615-g001">Figure 1</xref>
###xml 536 543 536 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t003">Table 3</xref>
###xml 548 556 548 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s001">Table S1</xref>
###xml 669 679 669 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s005">Figures S1</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s006">S2</xref>
###xml 716 725 716 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s005">Figure S1</xref>
###xml 1375 1384 1375 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s006">Figure S2</xref>
###xml 349 354 <span type="species:ncbi:9606">women</span>
###xml 358 361 <span type="species:ncbi:9606">men</span>
###xml 839 842 <span type="species:ncbi:9606">men</span>
###xml 898 903 <span type="species:ncbi:9606">women</span>
###xml 961 966 <span type="species:ncbi:9606">women</span>
###xml 971 974 <span type="species:ncbi:9606">men</span>
###xml 1514 1517 <span type="species:ncbi:9606">men</span>
###xml 1593 1598 <span type="species:ncbi:9606">women</span>
###xml 1723 1726 <span type="species:ncbi:9606">men</span>
###xml 1755 1760 <span type="species:ncbi:9606">women</span>
The study outline is presented in Figure 1. Initially, we studied the 46 genes in the FINRISK-92 case-cohort set. We selected for further study in the FINRISK-97 sample 27 genes in which one or more variants showed an association with CHD, ischemic stroke, CVD, total mortality, or any of the quantitative traits in the FINRISK-92 cohort, either in women or men separately, or in combined analyses. The selection criterion was 60% FDR. A total of 172 variants were thus typed also in the FINRISK-97 case-cohort samples, as indicated in Table 3 and Table S1, and analyzed using the combined FINRISK-92 and FINRISK-97 case-cohort sets. Power simulations are presented in Figures S1 and S2. For time-to-event analysis (Figure S1), the combination of the two cohorts has a 88% power to detect a dominant gene main effect on CVD risk of 1.8 in men at p = 0.01, a 39% power to detect a similar effect in women, and 96% power to detect this effect size when analyzing women and men together, given a risk allele frequency of 0.2 assuming a proportional hazards model. For a higher allele frequency the power is somewhat higher. For gene-gender interaction analysis, our study sample has power to detect only large differences in risk effects at p = 0.01, for example 38% power to detect a difference of HR = 1.0 versus HR = 1.8 for allele frequency of 0.4. For quantitative traits (Figure S2), combining both cohorts provides a power of 75% for detecting a 0.3 standard deviation difference at allele frequency of 0.2 in men at p = 0.01, while the power is much lower for the smaller study sample of women. For gene-gender interaction analyses the power is >85% only for large differences in the effects, for example no effect in men and a coefficient of 0.6 in women.
###end p 41
###begin title 42
Study outline.
###end title 42
###begin title 43
Time-to-event analysis results
###end title 43
###begin title 44
Analysis of both genders jointly
###end title 44
###begin p 45
###xml 227 234 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t004">Table 4</xref>
###xml 425 430 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGTR1</italic>
###xml 433 437 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 460 464 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPB2</italic>
###xml 495 498 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12</italic>
###xml 551 554 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12</italic>
###xml 634 637 630 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGA</italic>
###xml 690 699 686 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4976691</italic>
###xml 704 713 700 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1801020</italic>
###xml 786 795 782 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4976691</italic>
###xml 800 809 796 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1801020</italic>
###xml 1011 1016 1007 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1</italic>
###xml 1026 1035 1022 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs7178239</italic>
###xml 1225 1228 1219 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12</italic>
###xml 1237 1246 1231 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1801020</italic>
###xml 1700 1708 1694 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs440446</italic>
###xml 1712 1716 1706 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1119 1124 <span type="species:ncbi:9606">women</span>
###xml 1248 1251 <span type="species:ncbi:9606">men</span>
###xml 1256 1261 <span type="species:ncbi:9606">women</span>
###xml 1365 1370 <span type="species:ncbi:9606">women</span>
###xml 1375 1378 <span type="species:ncbi:9606">men</span>
Time-to-event analysis was used to assess the association between variants and CHD, ischemic stroke and the composite end point of CVD. Results with p</=0.01 from combined analysis of both cohorts and both genders are shown in Table 4. The estimated FDR for the set of all association tests (including tests for quantitative traits) with p</=0.01 is 53%. These analyses identified variants in angiotensin II receptor type 1 (AGTR1), APOE, carboxypeptidase B2 (CPB2), and coagulation factor XII (F12) as conferring risk of CHD. The two variants of the F12 gene also conferred risk of CVD, as did one variant of fibrinogen alpha chain (FGA) gene. Haplotype analysis for the two F12 variants, rs4976691 and rs1801020, in which carriers of the specific 'risk' haplotypes (CA, CG, or GA for rs4976691 and rs1801020, respectively) were compared to individuals homozygous for the non-risk haplotype GG did not reveal stronger association with CHD or CVD than analysis of single variants. For ischemic stroke, only one SEPS1 variant, rs7178239, was associated at p</=0.01 in the combined analysis of both genders, but only the women contributed to this effect (see below). The most consistent result was for CHD association with the F12 variant rs1801020 (men and women combined, p = 0.005 for additive model), which also conferred risk at the p<0.05 level for CHD in both women and men when analyzed separately. The rest of the variants showed association at p<0.05 level in only one gender. We tested whether the results were driven by only one of the cohorts by assessing genotype-cohort interaction, and observed no interaction at p<0.05, suggesting that the results are similar in both cohorts. Variant rs440446 of APOE showed association at p<0.05 also in both cohorts separately, while the rest of the variants showed association at p<0.05 in one cohort only, though a similar trend was observed in the other cohort.
###end p 45
###begin title 46
###xml 111 114 <span type="species:ncbi:9606">men</span>
###xml 119 124 <span type="species:ncbi:9606">women</span>
Results with p</=0.01for coronary heart disease and cardiovascular disease for the variants studied, analyzing men and women together.
###end title 46
###begin p 47
Time-to-event analysis, showing results for risk allele for the best model. Covariates used in analysis: geographic region, cohort, HDL-cholesterol, non-HDL cholesterol, body mass index, hypertension, smoking status, history of diabetes, and gender. P-values</=0.01 are in bold-face. P-values are not corrected for multiple testing.
###end p 47
###begin p 48
###xml 12 25 12 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12 rs4976691</italic>
###xml 51 60 51 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1787603</italic>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Results for F12 rs4976691 are similar to those for rs17876032, since they are in almost perfect LD (r2>0.96).
###end p 48
###begin title 49
Gender-genotype interactions
###end title 49
###begin p 50
###xml 411 419 407 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003615-g002">Figure 2</xref>
###xml 424 432 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s002">Table S2</xref>
###xml 726 730 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 735 740 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1</italic>
###xml 797 801 789 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 803 807 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 871 875 863 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 884 893 876 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 906 911 898 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1</italic>
###xml 922 931 914 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4965814</italic>
###xml 936 942 928 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs9874</italic>
###xml 952 956 944 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 965 974 957 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 1062 1071 1054 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 1313 1317 1305 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPB2</italic>
###xml 1363 1368 1355 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F13A1</italic>
###xml 1438 1442 1430 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPB2</italic>
###xml 1471 1473 1463 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5</italic>
###xml 1523 1526 1515 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 1560 1562 1552 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5</italic>
###xml 1571 1579 1563 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs970741</italic>
###xml 2162 2174 2154 2166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s003">Tables S3a&#8211;c</xref>
###xml 112 117 <span type="species:ncbi:9606">women</span>
###xml 122 125 <span type="species:ncbi:9606">men</span>
###xml 344 349 <span type="species:ncbi:9606">women</span>
###xml 353 356 <span type="species:ncbi:9606">men</span>
###xml 791 796 <span type="species:ncbi:9606">women</span>
###xml 1012 1017 <span type="species:ncbi:9606">women</span>
###xml 1404 1409 <span type="species:ncbi:9606">women</span>
###xml 1503 1506 <span type="species:ncbi:9606">men</span>
###xml 1630 1635 <span type="species:ncbi:9606">women</span>
###xml 2070 2073 <span type="species:ncbi:9606">men</span>
###xml 2078 2083 <span type="species:ncbi:9606">women</span>
###xml 2125 2131 <span type="species:ncbi:9606">person</span>
We performed gender-genotype interaction analysis to identify variants that showed different genetic effects in women and men. This test is sensitive to both effect direction and effect size. The variants that gave interaction p-value</=0.01 and were associated with CHD, ischemic stroke or the composite end-point of CVD at p</=0.01 in either women or men in combined analysis of both cohorts are presented in Figure 2 and Table S2. The estimated FDR for the set of all interaction tests with p</=0.01 is 70%, but by using the additional criteria of association p-value</=0.01 in at least one of the genders, the actual FDR is likely to be smaller. The gender-genotype interaction analysis supports our previous findings for USF1 and SEPS1 variants in which the disease risk was limited to women [30], [31], providing a gender-genotype interaction p-values<0.01 for the USF1 variant rs2774279 and for two SEPS1 variants, rs4965814 and rs9874. For the USF1 variant rs2774279, the results were also at p<0.05 for women in each cohort separately. Furthermore, for rs2774279 we also found evidence for association when analyzing prevalent female CHD cases in both cohorts combined (odds ratio of 1.58, 95% CI 1.04-2.40, p = 0.03). We identified variants in additional genes which showed gender-genotype interaction: CPB2 and coagulation factor XIII, A1 polypeptide (F13A1) conferred gender-specific risk in women for CHD, another variant in CPB2 conferred risk for CVD, and F5 for ischemic stroke; and for men, interleukin 6 (IL6) for CVD. The data obtained with F5 variant rs970741 is based on relatively small groups, with only 12 women incident stroke cases carrying the protective allele, and the result should be interpreted with caution. Genotype-cohort interaction analysis showed that none of the gender-specific results emerge from a strong effect in only one of the cohorts but rather both cohorts contribute to the result. For purpose of future meta-analyses, we provide data for all variants analyzed in both cohorts showing genotype-specific hazard ratios for men and women separately and number of individuals and person years in each genotype group (Tables S3a-c).
###end p 50
###begin title 51
Gender-specific association between variants and coronary heart disease, ischemic stroke, and cardiovascular disease.
###end title 51
###begin p 52
###xml 329 343 327 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPB2 rs3581419</italic>
###xml 348 357 346 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs3742264</italic>
###xml 360 361 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 372 386 370 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1 rs496581</italic>
###xml 391 400 389 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs7178239</italic>
###xml 403 404 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 415 427 413 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1 rs9874</italic>
###xml 432 441 430 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs7178239</italic>
###xml 444 445 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 485 493 483 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s002">Table S2</xref>
###xml 77 82 <span type="species:ncbi:9606">women</span>
###xml 86 89 <span type="species:ncbi:9606">men</span>
Results for gender-genotype interaction at p<0.05, and association in either women or men were at p</=0.01 (uncorrected p-values). Allele information: allele 1/allele 2, the minor allele is underlined. Multiplicative model: 11>12>22, dominant model: 11+12 vs 22, recessive model: 11 vs 12+22. Variants showing high pair-wise LD: CPB2 rs3581419 and rs3742264 (r2 = 0.827), SEPS1 rs496581 and rs7178239 (r2>0.7), and SEPS1 rs9874 and rs7178239 (r2>0.7). Detailed information is found in Table S2.
###end p 52
###begin p 53
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 147 156 147 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 187 196 187 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2073658</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 444 451 444 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 458 467 458 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2395754</italic>
We tested which of the variants conferring a CHD risk at p <0.05 were also associated with CHD in the prevalent cases. In addition to USF1 variant rs2774279, also the T allele of variant rs2073658 of USF1 conferred risk in both incident and prevalent female cases (HR = 1.62, 95% CI 1.04-2.52, p = 0.03 for incident cases, and odds ratio = 1.87, 95% CI 1.26-2.76, p = 0.002 for prevalent cases, additive model, T risk allele). A variant in the APOBEC2 gene, rs2395754, was associated with CHD in both prevalent and incident male cases (HR = 1.45, 95% CI 1.04-2.02, p = 0.03 for incident cases, and odds ratio = 1.43, 95% CI 1.06-1.94, p = 0.02 for prevalent cases, C allele homozygotes compared to T allele carriers).
###end p 53
###begin title 54
Quantitative trait analysis results
###end title 54
###begin p 55
###xml 396 403 396 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t005">Table 5</xref>
###xml 698 702 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 711 719 709 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs440446</italic>
###xml 772 779 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t004">Table 4</xref>
###xml 827 830 825 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGA</italic>
###xml 839 848 837 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2070018</italic>
###xml 1038 1043 <span type="species:ncbi:9606">women</span>
###xml 1048 1051 <span type="species:ncbi:9606">men</span>
We tested whether any of the 172 variants was associated with the CVD-related quantitative traits: total cholesterol, HDL-C, LDL-C, triglycerides, CRP, BMI, WHR and mean blood pressure, analyzing the sub-cohort individuals without a history of CVD at baseline examination. The results showing association in the combined data analyses of both genders at significance level of p<0.01 are shown in Table 5. The estimated FDR for the set of all association tests (including tests for time-to-event responses) with p</=0.01 is 53%. We identified 3 variants displaying effect differences between the cohorts using genotype-cohort interaction analysis (interaction p-value <0.05), and they were removed. APOE variant rs440446, conferring risk for CHD in time-to-event analysis (Table 4), was associated with triglyceride values, and FGA variant rs2070018 was associated with mean blood pressure, with heterozygotes having the highest blood pressure values. None of the other variants associated with CHD, ischemic stroke, or CVD at p</=0.01 in women and men combined, was associated at p<0.01 with the quantitative traits tested here. However, we identified several interesting associations with each of the traits studied, as discussed below.
###end p 55
###begin title 56
###xml 161 166 <span type="species:ncbi:9606">women</span>
###xml 171 174 <span type="species:ncbi:9606">men</span>
Results with p<0.01for associations between variants and quantitative traits as measured at baseline examination in sub-cohort subjects free of CVD at baseline, women and men combined.
###end title 56
###begin p 57
For most variants, showing results for additive model (add). Exception is for trait/variant combination in which one of the genotyping groups has <5 individuals, for which the comparison is made between minor allele carriers and non-carriers. Also, showing variants for which the association at p<0.01 is obtained only for minor allele dominant (dom) or recessive (rec) model.
###end p 57
###begin p 58
covariates used in analysis: age at baseline, geographic region, cohort, and gender.
###end p 58
###begin p 59
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 67 79 67 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5 rs2269648</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6029</italic>
###xml 92 105 92 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT rs4988235</italic>
###xml 110 118 110 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs182549</italic>
###xml 120 133 120 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT rs6719488</italic>
###xml 138 147 138 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2236783</italic>
These variant pairs show similar results due to high LD (r2>0.96): F5 rs2269648 and rs6029, LCT rs4988235 and rs182549, LCT rs6719488 and rs2236783.
###end p 59
###begin p 60
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUT3</italic>
###xml 147 157 147 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs11673407</italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUT3</italic>
###xml 354 362 354 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs874232</italic>
###xml 364 372 364 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs778986</italic>
###xml 378 388 378 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs11673407</italic>
###xml 497 506 497 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s004">Table S4a</xref>
###xml 640 643 640 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 653 662 653 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1800947</italic>
###xml 89 94 <span type="species:ncbi:9606">women</span>
###xml 99 102 <span type="species:ncbi:9606">men</span>
###xml 171 174 <span type="species:ncbi:9606">men</span>
###xml 224 229 <span type="species:ncbi:9606">women</span>
###xml 326 329 <span type="species:ncbi:9606">men</span>
###xml 682 685 <span type="species:ncbi:9606">men</span>
The strongest association identified for quantitative traits in the combined analysis of women and men was for fucosyltransferase 3 (FUT3) variant rs11673407 and WHR. For men the additive model gave a p-value = 0.00006; for women the association was weaker, but in the same direction (p = 0.07). Haplotype analysis for WHR in men using the FUT3 variants rs874232, rs778986, and rs11673407 identified haplotype CAG as the only one associated with WHR, compared to base haplotype TAA (p = 0.00008) (Table S4a), suggesting that the true causal variant is not one of these 3 variants. Another strong association was found for a rare synonymous CRP variant, rs1800947, and CRP levels in men (p = 0.0001, recessive model).
###end p 60
###begin p 61
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 174 183 174 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4988235</italic>
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUT3</italic>
###xml 357 366 357 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4988235</italic>
###xml 371 380 371 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6719488</italic>
###xml 449 458 449 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4988235</italic>
###xml 463 472 463 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6719488</italic>
###xml 616 625 616 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2304371</italic>
###xml 627 636 627 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6719488</italic>
###xml 642 651 642 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs4988235</italic>
###xml 722 731 722 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2304371</italic>
###xml 863 872 863 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003615.s004">Table S4b</xref>
###xml 922 931 922 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2304371</italic>
###xml 1107 1116 1107 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs6719488</italic>
###xml 1121 1130 1121 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2304371</italic>
###xml 1150 1153 1150 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 1254 1257 1254 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 1268 1271 1268 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 1478 1482 1478 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Enattah2">[55]</xref>
###xml 1609 1610 1609 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 292 295 <span type="species:ncbi:9606">men</span>
###xml 656 659 <span type="species:ncbi:9606">men</span>
###xml 886 889 <span type="species:ncbi:9606">men</span>
###xml 1343 1348 <span type="species:ncbi:9606">human</span>
The LCT variants were associated with total cholesterol and LDL-C in the combined data: The lactase non-persistence genotype (defined as minor allele homozygotes for variant rs4988235) was associated with higher cholesterol values. Similarly to FUT3 variant, the association was stronger for men (for total cholesterol, p = 0.003 and p = 0.005 for variants rs4988235 and rs6719488, respectively, and for LDL-C p = 0.002, and p = 0.0005 for variants rs4988235 and rs6719488, respectively), and in females the association was weaker but in the same direction. Haplotype analysis using the 3 haplotype-tagging variants rs2304371, rs6719488, and rs4988235 for men implied that haplotype GGG, tagged by the G allele of variant rs2304371 was the one associated with both traits, p = 0.003 for total cholesterol and p = 0.005 for LDL-C (compared to base haplotype ATA) (Table S4b). Sub-cohort men homozygotes for the G allele of rs2304371 have the highest LDL-C values, 4.02 mmol/l (n = 14), compared to 3.74 for GA genotype (n = 109) and 3.55 for AA genotype (n = 243), p = 0.014 for the additive model. Variants rs6719488 and rs2304371 are located in the LCT gene itself, while the lactase non-persistence variant is located at 14 kb distance upstream of the LCT gene. The LCT locus on chromosome 2q21.3 is known for being strongly selected during human evolution, with the lactase persistence allele varying in frequency in different populations and even between geographic regions [55]. We observed no differences in allele frequencies of the lactase persistence genotype in the geographic regions studied here (G allele frequency 0.46 in Western Finland and 0.44 in Eastern Finland).
###end p 61
###begin p 62
###xml 104 111 104 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t006">Table 6</xref>
###xml 632 635 628 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGA</italic>
###xml 640 643 636 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGG</italic>
###xml 895 899 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 908 917 904 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2774279</italic>
###xml 1120 1125 1116 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ICAM1</italic>
###xml 77 82 <span type="species:ncbi:9606">women</span>
###xml 87 90 <span type="species:ncbi:9606">men</span>
###xml 202 207 <span type="species:ncbi:9606">women</span>
###xml 211 214 <span type="species:ncbi:9606">men</span>
###xml 573 578 <span type="species:ncbi:9606">women</span>
###xml 583 586 <span type="species:ncbi:9606">men</span>
###xml 591 596 <span type="species:ncbi:9606">women</span>
###xml 773 778 <span type="species:ncbi:9606">women</span>
###xml 888 893 <span type="species:ncbi:9606">women</span>
###xml 995 1000 <span type="species:ncbi:9606">women</span>
###xml 1045 1050 <span type="species:ncbi:9606">Women</span>
###xml 1154 1159 <span type="species:ncbi:9606">women</span>
Variants that showed different effects on CVD-related quantitative traits in women and men are shown in Table 6, using an interaction p-value cut off </=0.01 and an association cut off p<0.01 in either women or men in combined analysis of both cohorts. The estimated FDR for the set of all interaction tests with p</=0.01 is 70%, but the additional criteria of association p-value<0.01 in at least one of the genders makes the actual FDR smaller than the upper limit of 70%. As for the disease risk, also here variants in different genes were associated with the traits in women and men. In women, variants in the fibrinogen genes (FGA and FGG) were associated with HDL-C. Interestingly, none of the genes that are in lipid pathways were associated with lipid variables in women at p<0.01. For weight-related variables, variants that showed gender-specific effect were identified only in women. USF1 variant rs2774279, which was associated with CHD and CVD risk, was also associated with BMI in women, though risk allele carriers had lower BMI. Women with the risk allele also had lower values of CRP. Three variants in ICAM1 gene associated with WHR in women. Haplotype analysis did not reveal any ICAM1 haplotypes associated more strongly with the trait than single alleles. The largest number of gender-genotype interactions was identified for CRP levels in females.
###end p 62
###begin title 63
###xml 187 192 <span type="species:ncbi:9606">women</span>
###xml 197 200 <span type="species:ncbi:9606">men</span>
Results with p<0.01 for associations between variant and quantitative traits as measured at baseline examination, for variants showing evidence of gender-genotype interaction (p</=0.01), women and men of the sub-cohort free of CVD at baseline.
###end title 63
###begin p 64
Regression analysis, using as covariates geographic region, cohort, age.
###end p 64
###begin p 65
###xml 97 100 <span type="species:ncbi:9606">men</span>
###xml 105 110 <span type="species:ncbi:9606">women</span>
Interaction p-value tests the null hypothesis that the genotype effect in regression analysis in men and women does not differ from each other.
###end p 65
###begin p 66
Uncorrected p-values.
###end p 66
###begin p 67
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 37 51 37 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ICAM1 rs281432</italic>
###xml 56 65 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs5030352</italic>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 77 89 77 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5 rs2227245</italic>
###xml 94 103 94 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs7542281</italic>
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2227245</italic>
High pair-wise LD: r2 = 0.80 between ICAM1 rs281432 and rs5030352, r2 = 0.97 F5 rs2227245 and rs7542281 therefore results for rs2227245 not shown.
###end p 67
###begin p 68
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 29 38 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2395754</italic>
###xml 441 448 441 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003615-t006">Table 6</xref>
###xml 4 7 <span type="species:ncbi:9606">men</span>
###xml 152 155 <span type="species:ncbi:9606">Men</span>
###xml 223 226 <span type="species:ncbi:9606">men</span>
###xml 493 496 <span type="species:ncbi:9606">men</span>
###xml 550 555 <span type="species:ncbi:9606">women</span>
For men, the APOBEC2 variant rs2395754, which associated with CHD in both incident and prevalent cases, was also associated with cholesterol variables. Men carrying the risk allele had higher levels of LDL-C, p = 0.001. In men also a variant in the serpin peptidase inhibitor, clade E member 1 gene was associated with mean blood pressure. In addition to these findings, very few male-specific results at p<0.01 were identified, as shown in Table 6. The strongest associations with lipids for men were for variants that also showed the same trend in women, as discussed above.
###end p 68
###begin title 69
Discussion
###end title 69
###begin p 70
###xml 408 412 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Rinn1">[56]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Mendelsohn1">[57]</xref>
###xml 701 704 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-BarrettConnor1">[2]</xref>
###xml 706 710 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Mendelsohn1">[57]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Mendelsohn1">[57]</xref>
###xml 146 151 <span type="species:ncbi:9606">human</span>
The hormonal environment as well as tissue specific gene expression is known to differ significantly between the genders in vertebrates. For many human diseases, gender-dependent differences in the progression and extent of disease have been explained by sex hormones. These hormones may differentially affect gene expression in somatic tissues, thus leading to the gender specific susceptibility to disease [56]. Also for cardiovascular disease, critical determinants of gender differences are sex steroid hormones and their receptors [57]. They interact with and activate, together with other proteins, genes that are possibly involved in CVD pathogenesis in the endothelial and smooth muscle cells [2], [57]. Sex steroid hormones are also expressed in the liver and regulate lipid levels, mostly through hepatic effects on lipoprotein metabolism [57].
###end p 70
###begin p 71
###xml 84 87 84 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-BarrettConnor1">[2]</xref>
###xml 88 91 88 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Pilote1">[4]</xref>
###xml 93 96 93 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-TunstallPedoe2">[6]</xref>
###xml 98 101 98 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Yusuf1">[7]</xref>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy1">[12]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Helgadottir1">[14]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Samani1">[17]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Wellcome1">[19]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Schunkert1">[58]</xref>
###xml 1751 1755 1751 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Patsopoulos1">[59]</xref>
###xml 2099 2103 2099 2103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Helgadottir1">[14]</xref>
###xml 2105 2109 2105 2109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McPherson1">[16]</xref>
###xml 2111 2115 2111 2115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Samani1">[17]</xref>
###xml 2117 2121 2117 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Wellcome1">[19]</xref>
###xml 2123 2127 2123 2127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Matarin1">[28]</xref>
###xml 9 14 <span type="species:ncbi:9606">women</span>
###xml 19 22 <span type="species:ncbi:9606">men</span>
###xml 177 182 <span type="species:ncbi:9606">women</span>
###xml 187 190 <span type="species:ncbi:9606">men</span>
###xml 457 460 <span type="species:ncbi:9606">men</span>
###xml 465 470 <span type="species:ncbi:9606">women</span>
###xml 1104 1107 <span type="species:ncbi:9606">men</span>
###xml 1112 1117 <span type="species:ncbi:9606">women</span>
###xml 1286 1289 <span type="species:ncbi:9606">men</span>
###xml 1294 1299 <span type="species:ncbi:9606">women</span>
###xml 1848 1851 <span type="species:ncbi:9606">men</span>
###xml 1856 1861 <span type="species:ncbi:9606">women</span>
Although women and men differ in various aspects related to CHD and ischemic stroke [2]-[4], [6], [7], the difference in genetic effects on disease and its risk factors between women and men remains largely unexplored territory [12]. Recent genome-wide association studies also do not address this issue [14]-[17], [19], [58]. In this candidate gene study we explored the genetic risk profiles for CHD, ischemic stroke and the composite end point of CVD in men and women, as well as the effect of the specific genetic variants on CVD-related quantitative risk factors. Our case-cohort study was based on two prospective cohorts from the relatively homogeneous Finnish population, the sub-cohort representing a random subsample of the original cohort. Detailed information on CVD risk factors recorded before the occurrence of CVD events allowed us to control for confounding factors, such as smoking, lipid levels, blood pressure and obesity, while the inclusion of two separate cohorts allowed for the verification of results. We identified variants in several genes as conferring disease risk for both men and women jointly, while other variants showed evidence for a gender-specific effect. We also identified variants that were associated with quantitative CVD risk factors in both men and women combined, and other variants that showed evidence for gender-genotype interaction. A recent review of gender differences in genetic effects has suggested three criteria for appropriately documented gender differences: (1) The genetic effect is based on the same genetic contrast in both genders; (2) Different genetic subsets in the 2 genders are not compared; and (3) Evidence for a nominally statistically significant gender-gene interaction exists [59]. Our study fulfils all these criteria for the genetic variants showing different effects in men and women. However, studies that replicate these results in larger study samples would be required to confirm or refute the gender-specific associations presented here. With pooling of information across the latest genome-wide association studies [14], [16], [17], [19], [28], there is ample opportunity to test for the presence of gender-genotype interactions behind CHD and ischemic stroke at a genomic level.
###end p 71
###begin p 72
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPB2</italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F13A1</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPIN1</italic>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Komulainen1">[31]</xref>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USF1</italic>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Lee1">[60]</xref>
###xml 419 421 419 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F5</italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEPS1</italic>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Alanne1">[30]</xref>
###xml 690 693 690 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 926 930 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-McCarthy3">[27]</xref>
###xml 1046 1050 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Touze1">[11]</xref>
###xml 1052 1056 1050 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Pilia1">[13]</xref>
###xml 555 560 <span type="species:ncbi:9606">women</span>
###xml 641 646 <span type="species:ncbi:9606">women</span>
###xml 656 659 <span type="species:ncbi:9606">men</span>
###xml 665 668 <span type="species:ncbi:9606">men</span>
###xml 920 925 <span type="species:ncbi:9606">women</span>
###xml 1040 1045 <span type="species:ncbi:9606">women</span>
###xml 1147 1152 <span type="species:ncbi:9606">women</span>
###xml 1164 1167 <span type="species:ncbi:9606">men</span>
In this study, we identified variants in CPB2, F13A1 and LPIN1 as contributing to female-specific risk for CHD and/or CVD, in addition to a variant in USF1 which we have previously reported [31]. Other variants of USF1 have also been reported as showing significant gender-genotype interaction for triglycerides and BMI in familial combined hyperlipidemia families [60]. For ischemic stroke, we identified a variant in F5 as conferring gender-specific risk, in addition to our previously reported association between SEPS1 variants and ischemic stroke in women [30]. Importantly, we identified a larger number of gender-specific effects for women than for men. For men, only one variant in IL6 gene was associated with CVD at p</=0.01 and interaction p<0.01. The asymmetry in positive results is similar to a previous large scale candidate gene study of the metabolic syndrome, in which genetic effects were stronger in women [27]. This is also consistent with the larger heritability estimates for stroke and several CVD-related traits in women [11], [13]. These results suggest that genetic effects on CVD risk may be more readily detectable in women, while for men the genetic effects are more confounded by environmental/lifestyle risk factors.
###end p 72
###begin p 73
###xml 103 106 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12</italic>
###xml 113 122 113 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs1801020</italic>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Endler1">[61]</xref>
###xml 545 548 545 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F12</italic>
###xml 791 795 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUT3</italic>
###xml 802 812 802 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs11673407</italic>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Salomaa1">[62]</xref>
###xml 924 932 924 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs778986</italic>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Cakir1">[63]</xref>
###xml 56 61 <span type="species:ncbi:9606">women</span>
###xml 66 69 <span type="species:ncbi:9606">men</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
The most consistent result we identified when analyzing women and men jointly was for a variant in the F12 gene, rs1801020. This promoter variant is located in the untranslated exon 1 of the gene, and the T allele was found to be less common in patients with acute coronary syndrome compared to patients with stable coronary artery disease [61]. In our study sample, in which the A ( = T) allele was associated with risk of CHD and CVD, the study setting was very different, and therefore the results are not readily comparable. Variants in the F12 gene were not present in the Affymetrix 500K and Illumina 300K chips that have been used for the recent genome-wide association studies. The strongest association for quantitative trait variable was between WHR and an intronic variant of the FUT3 gene, rs11673407. The associated variant is not one of the four variants previously associated with Lewis blood phenotype [62] (rs778986 studied here) and which have been reported to be associated with several CVD-related risk factors [63].
###end p 73
###begin p 74
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 297 300 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 434 443 434 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2304371</italic>
###xml 623 630 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 708 715 708 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 789 796 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC1</italic>
###xml 796 800 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Liao1">[64]</xref>
###xml 856 860 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Lau1">[65]</xref>
###xml 862 869 862 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOBEC2</italic>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003615-Liao1">[64]</xref>
###xml 656 659 <span type="species:ncbi:9606">men</span>
Two of the genes we selected to this study, LCT and APOBEC2, have not been previously associated with molecular pathogenesis of cardiovascular disease. We found association between LCT variants and both total and LDL cholesterol. Haplotype analysis implied that the associated variants are in the LCT gene itself, and not necessarily related to the lactase persistence variant upstream of the gene. The C allele of the exonic variant rs2304371, which was associated with highest cholesterol values, is the ancestral allele, present in other mammals and located in a highly conserved region. We also found that a variant in APOBEC2 conferred risk of CHD in men and was associated with higher levels of LDL-C. APOBEC2 belongs to the cytidine deaminase superfamily, and is closely related to APOBEC1[64]. APOBEC1 mediates the editing of apolipoprotein B mRNA [65]. APOBEC2 is expressed exclusively in heart and skeletal muscle [64], and its function is still largely unknown.
###end p 74
###begin p 75
###xml 265 270 <span type="species:ncbi:9606">women</span>
###xml 275 278 <span type="species:ncbi:9606">men</span>
###xml 802 805 <span type="species:ncbi:9606">men</span>
###xml 809 814 <span type="species:ncbi:9606">women</span>
To summarize, we have identified several variants of relevant candidate genes that may confer risk of CHD, ischemic stroke or CVD and/or associate with quantitative CVD-risk factors in a gender-specific manner, and other variants which probably confer risk in both women and men. The identified disease associations and quantitative trait associations had uncorrected p-values</=0.01 for both genders combined and on the basis of the FDR analysis we expect that half of the findings are true positives. For interaction analysis, we may expect that at least third of the reported results are true positives. However, the FDR analysis for the interaction analysis is conservative, because it does not account for the additional criteria we used of association p-value<0.01 for the trait itself in either men or women. Thus, we are convinced that some of the results represent a real effect of variants on disease/trait, but obviously require replication in other studies. In addition, our study had low power to detect genetic effects with HR<1.8 or coefficient<0.3, thus some of the variants we have studied that show no genetic effect might represent false negative results. The possible differences in genetic risk profiles between the genders should be addressed in more detail in genetic studies of CVD, and more focus on female CVD risk is warranted also in genome-wide association studies.
###end p 75
###begin title 76
Supporting Information
###end title 76
###begin p 77
The genetic variants analyzed in the current study
###end p 77
###begin p 78
(0.09 MB XLS)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
Gender-specific results (p</=0.01, uncorrected), in which there was gender-genotype interaction (p</=0.01, uncorrected) in coronary heart disease, ischemic stroke and cardiovascular disease
###end p 80
###begin p 81
(0.06 MB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 33 38 <span type="species:ncbi:9606">women</span>
###xml 43 46 <span type="species:ncbi:9606">men</span>
Genotype association results for women and men (uncorrected p-values) for coronary heart disease (a), ischemic stroke (b) and cardiovascular disease (c)
###end p 83
###begin p 84
(0.27 MB XLS)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 105 108 <span type="species:ncbi:9606">men</span>
###xml 227 230 <span type="species:ncbi:9606">men</span>
(a) Haplotype analysis for body mass index (BMI) and waist/hip ratio (WHR) for FUT3 variants, sub-cohort men free of CVD at baseline; (b)Haplotype analysis for total cholesterol and LDL cholesterol for LCT variants, sub-cohort men free of CVD at baseline.
###end p 86
###begin p 87
(0.05 MB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
###xml 200 203 <span type="species:ncbi:9606">men</span>
###xml 246 251 <span type="species:ncbi:9606">women</span>
Power simulations for time-to-event analysis for risk allele frequencies of 0.2 and 0.4, combining both cohorts, using p-value cut-off of 0.01 and assuming for interaction analysis (IA) no effect for men while testing different effect values for women. The lines connect different value points and are not interpolations. HR = hazard ratio.
###end p 89
###begin p 90
(7.13 MB TIF)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
###xml 234 237 <span type="species:ncbi:9606">men</span>
###xml 280 285 <span type="species:ncbi:9606">women</span>
Power simulations for quantitative trait analysis using BMI as an example, testing risk allele frequencies of 0.2 and 0.4, combining both cohorts, using p-value cut-off of 0.01 and assuming for interaction analysis (IA) no effect for men while testing different effect values for women. The lines connect different value points and are not interpolations. Regression coefficients are given in standard deviation scale. BMI = body mass index.
###end p 92
###begin p 93
(7.13 MB TIF)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGTR1</italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 489 492 489 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCT</italic>
We warmly thank all the Finnish volunteers who participated in the FINRISK-92 and FINRISK-97 studies. KTL Analytical Biochemistry laboratory is acknowledged for the laboratory measurements. Thanks are due to Siv Knaappila, Minna Suvela, Arja Tapio, and Anne Nyberg for their fastidious laboratory work. Minttu Jussila and Elina Makinen are acknowledged for DNA aliquotting. Reetta Rautiainen, Tuuli Kauttu, and Aimee Trudeau are acknowledged for partially genotyping the AGTR1, APOA5, and LCT variants, respectively. Zygimantas Cepaitis, Ari Haukijarvi and Dr. Bijoy Joseph from the MORGAM Data Center and Juha Knuuttila and Juri Ahokas from the Genome Informatics Unit at the National Public Health Institute are acknowledged for data handling.
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
###xml 51 56 <span type="species:ncbi:9606">women</span>
Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture.
###end article-title 97
###begin article-title 98
###xml 119 122 <span type="species:ncbi:9606">men</span>
###xml 127 132 <span type="species:ncbi:9606">women</span>
Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland.
###end article-title 98
###begin article-title 99
A comprehensive view of sex-specific issues related to cardiovascular disease.
###end article-title 99
###begin article-title 100
Myth and paradox of coronary risk and the menopause.
###end article-title 100
###begin article-title 101
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
###end article-title 101
###begin article-title 102
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
###end article-title 102
###begin article-title 103
Genetic liability in stroke: a long-term follow-up study of Danish twins.
###end article-title 103
###begin article-title 104
The genetics of coronary heart disease: the contribution of twin studies.
###end article-title 104
###begin article-title 105
Genetics of atherosclerosis.
###end article-title 105
###begin article-title 106
###xml 36 41 <span type="species:ncbi:9606">women</span>
###xml 56 59 <span type="species:ncbi:9606">men</span>
Heritability of ischaemic stroke in women compared with men: a genetic epidemiological study.
###end article-title 106
###begin article-title 107
Gene by sex interaction in the etiology of coronary heart disease and the preceding metabolic syndrome.
###end article-title 107
###begin article-title 108
Heritability of cardiovascular and personality traits in 6,148 Sardinians.
###end article-title 108
###begin article-title 109
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
###end article-title 109
###begin article-title 110
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes.
###end article-title 110
###begin article-title 111
A common allele on chromosome 9 associated with coronary heart disease.
###end article-title 111
###begin article-title 112
Genomewide association analysis of coronary artery disease.
###end article-title 112
###begin article-title 113
Genetics of ischemic stroke: future clinical applications.
###end article-title 113
###begin article-title 114
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 114
###begin article-title 115
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes.
###end article-title 115
###begin article-title 116
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.
###end article-title 116
###begin article-title 117
Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol.
###end article-title 117
###begin article-title 118
Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction.
###end article-title 118
###begin article-title 119
Assessment of genetic risk for myocardial infarction.
###end article-title 119
###begin article-title 120
Genetic risk for ischemic and hemorrhagic stroke.
###end article-title 120
###begin article-title 121
Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.
###end article-title 121
###begin article-title 122
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients.
###end article-title 122
###begin article-title 123
###xml 34 42 <span type="species:ncbi:9606">patients</span>
A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release.
###end article-title 123
###begin article-title 124
MORGAM (an international pooling of cardiovascular cohorts).
###end article-title 124
###begin article-title 125
Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent Finnish cohorts.
###end article-title 125
###begin article-title 126
###xml 60 65 <span type="species:ncbi:9606">women</span>
Risk alleles of USF1 gene predict cardiovascular disease of women in two prospective studies.
###end article-title 126
###begin article-title 127
Cardiovascular risk factor changes in Finland, 1972-1997.
###end article-title 127
###begin article-title 128
Thrombomodulin gene polymorphisms and haplotypes and the risk of cardiovascular events: a prospective follow-up study.
###end article-title 128
###begin article-title 129
Case-cohort design in practice-experiences from the MORGAM Project.
###end article-title 129
###begin article-title 130
Description of MORGAM Cohorts.
###end article-title 130
###begin article-title 131
Evaluating whole genome amplification via multiply-primed rolling circle amplification for SNP genotyping of samples with low DNA yield.
###end article-title 131
###begin article-title 132
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
###end article-title 132
###begin article-title 133
Identification of a variant associated with adult-type hypolactasia.
###end article-title 133
###begin article-title 134
###xml 115 120 <span type="species:ncbi:9606">human</span>
Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism.
###end article-title 134
###begin article-title 135
###xml 57 62 <span type="species:ncbi:9606">human</span>
Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene.
###end article-title 135
###begin article-title 136
###xml 56 61 <span type="species:ncbi:9606">human</span>
Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism.
###end article-title 136
###begin article-title 137
The enhancement of homogenous mass extension reaction: comparison of two enzymes.
###end article-title 137
###begin article-title 138
Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample.
###end article-title 138
###begin article-title 139
Combined effects of thrombosis pathway gene variants predict cardiovascular events.
###end article-title 139
###begin article-title 140
Analysis of genetic variation in the GenomEUtwin project.
###end article-title 140
###begin article-title 141
PedCheck: a program for identification of genotype incompatibilities in linkage analysis.
###end article-title 141
###begin article-title 142
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 142
###begin article-title 143
A case-cohort design for epidemiologic cohort studies and disease prevention trials.
###end article-title 143
###begin article-title 144
The haplo.stats Package, version 1.3.1.
###end article-title 144
###begin article-title 145
Empirical Bayes analysis of a microarray experiment.
###end article-title 145
###begin article-title 146
Large-scale simultaneous hypothesis testing: The choice of a null hypothesis.
###end article-title 146
###begin article-title 147
The fdrtool Package, version 1.1.4.
###end article-title 147
###begin article-title 148
###xml 54 59 <span type="species:ncbi:9606">women</span>
Hypolactasia and metabolic changes in post-menopausal women.
###end article-title 148
###begin article-title 149
Serum lipids and proteins in lactose malabsorption.
###end article-title 149
###begin article-title 150
###xml 94 100 <span type="species:ncbi:9606">humans</span>
Evidence of still-ongoing convergence evolution of the lactase persistence T-13910 alleles in humans.
###end article-title 150
###begin article-title 151
Sexual dimorphism in mammalian gene expression.
###end article-title 151
###begin article-title 152
Molecular and cellular basis of cardiovascular gender differences.
###end article-title 152
###begin article-title 153
Repeated Replication and a Prospective Meta-Analysis of the Association Between Chromosome 9p21.3 and Coronary Artery Disease.
###end article-title 153
###begin article-title 154
Claims of sex differences: an empirical assessment in genetic associations.
###end article-title 154
###begin article-title 155
USF1 Contributes to High Serum Lipid Levels in Dutch FCHL Families and U.S. Whites With Coronary Artery Disease.
###end article-title 155
###begin article-title 156
Homozygosity for the C-->T polymorphism at nucleotide 46 in the 5' untranslated region of the factor XII gene protects from development of acute coronary syndrome.
###end article-title 156
###begin article-title 157
Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study.
###end article-title 157
###begin article-title 158
Association of the Lewis genotype with cardiovascular risk factors and subclinical carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study.
###end article-title 158
###begin article-title 159
APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family.
###end article-title 159
###begin article-title 160
###xml 23 28 <span type="species:ncbi:9606">human</span>
Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene.
###end article-title 160
###begin p 161
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 161
###begin p 162
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was part of the GenomEUtwin project (), which was supported by the European Commission under the programme 'Quality of Life and Management of the Living Resources' of 5th Framework Programme (no. QLG2-CT-2002-01254). This study was supported by the Nordic Centre of Excellence is Disease Genetics (), the Academy of Finland Centre of Excellence in Complex Disease Genetics (), and Biocentrum Helsinki (). The Sigrid Juselius Foundation has supported Veikko Salomaa and Markus Perola. Jenny and Antti Wihuri Foundation, Aarne Koskelo Foundation, the Finnish Foundation for Cardiovascular Research, the Research Foundation of Orion Corporation, and the Paulo Foundation are acknowledged for their financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 162

